Loading
NYSEHealthcareMedical - Diagnostics & Research
Latest quote
$154.96
+$2.80 · +1.84%
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Regular session
$154.96
+$2.80 · +1.84%
Regular session · ET · Market data may be delayed.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Day range
Current $154.96
52-week range
Current $154.96
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
56
Mixed
Risk
34
Moderate Risk
Momentum
52
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Day range
Current $154.96
52-week range
Current $154.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.86B USD | 2.76B USD | 2.75B USD | 3.31B USD | 3.83B USD |
| Cost of goods sold | 1.34B USD | 1.43B USD | 1.43B USD | 1.55B USD | 1.55B USD |
| Gross profit | 1.52B USD | 1.32B USD | 1.32B USD | 1.76B USD | 2.28B USD |
| Research and development | 215.84M USD | 196.84M USD | 216.58M USD | 221.62M USD | 200.34M USD |
| Selling, general, and administrative | 945.29M USD | 715.3M USD | 706.12M USD | 757.99M USD | 741.61M USD |
| Operating expenses | 1.16B USD | 912.14M USD | 922.7M USD | 979.61M USD | 941.95M USD |
| Interest income | 31.1M USD | 73.19M USD | 72.13M USD | 3.59M USD | 2.24M USD |
| Interest expense | 92.19M USD | 96.28M USD | 98.81M USD | 103.96M USD | 102.13M USD |
| Depreciation and amortization | 405.34M USD | 427.85M USD | 431.77M USD | 427M USD | 311.44M USD |
| Operating income | 356.64M USD | 410.52M USD | 399.49M USD | 781.12M USD | 1.34B USD |
| Net income | 241.68M USD | 295.83M USD | −118.38M USD | 569.18M USD | 943.16M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T33.06B0.03%129.69T JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI456.17M0.02%2.3T USD0.03%$382.03+0.65%
Vanguard S&P 500 ETFVOO381.36M0.02%1.8T USD0.03%$715.7+0.62%
Vanguard Morningstar Small-Cap ETFVB330.28M0.18%185.3B USD0.03%$289.66+0.70%
iShares Core S&P 500 ETFIVV225.75M0.03%897.2B USD0.03%$782.04+0.61%
Vanguard Morningstar Small-Cap Value ETFVBR209.75M0.31%68.2B USD0.05%$234.64+0.31%
State Street SPDR S&P 500 ETFSPY208.88M0.03%821.54B USD0.09%$778.57+0.60%
Dimensional - US Targeted Value ETFDFAT148.92M0.50%30.26B USD0.33%$67.45-0.16%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBiShares Core S&P 500 ETFIVVVanguard Morningstar Small-Cap Value ETFVBRState Street SPDR S&P 500 ETFSPYDimensional - US Targeted Value ETFDFATAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
